RxDoctor Payments Data

Jose Rodriguez Moreno, MD

Neurology · Medford, ORNPI 1891148854

Payments from drug & device makers

$2,554in general payments, 2019–2025

Across 38 payments — averaging $67.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Argenx US, Inc.$371
  • AbbVie$157
  • Otsuka America Pharmaceutical, Inc.$110
  • Biogen$77
  • Portola Pharmaceuticals, LLC$59
  • plus $257 from 11 others

What the payments were for

  • Travel & lodging$1,32552%
  • Food & beverage$1,15645%
  • Education$733%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,554 in reported general payments places this provider in the 65th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$206,621
Medicare patients
500
Services billed
18,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$193,830
TecfideraDimethyl Fumarate14$123,867
HizentraImmun Glob G(Igg)/Pro/Iga 0-5018$108,542
Nurtec OdtRimegepant Sulfate63$98,121
CopaxoneGlatiramer Acetate17$88,721
Aimovig AutoinjectorErenumab-Aooe69$73,567
NuplazidPimavanserin Tartrate13$63,922
RytaryCarbidopa/Levodopa35$31,988
Lacosamide189$29,448
UbrelvyUbrogepant26$27,922
QuliptaAtogepant12$27,301
Carbidopa-LevodopaCarbidopa/Levodopa747$26,581
Ajovy AutoinjectorFremanezumab-Vfrm26$22,193
Carbidopa-Levodopa ErCarbidopa/Levodopa342$17,434
Levetiracetam301$12,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$22$193,83026 claims
BiogenTecfidera$77$123,86714 claims
CSL BehringHizentra$20$108,54218 claims
Teva Pharmaceuticals USA, Inc.Copaxone$58$88,72117 claims
AbbVieUbrelvy, Qulipta$157$55,22338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 228 neurology providers in Oregon.

Other neurology in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →